作者: L. Liaudet , M. D. Schaller , F. Feihl
DOI: 10.1007/978-3-642-72038-3_15
关键词:
摘要: In spite of major advances in the care critically ill patients, septic shock remains a commonly fatal condition, with mortality rate averaging 50% [1], Recent progress understanding pathophysiology has prompted an intense search for new therapeutic modalities. particular, recognition that enhanced production vasodilator nitric oxide (NO) from inducible isoform NO synthase (iNOS) plays role sepsis-induced hypotension, suggested pharmacological inhibition iNOS might be great value this setting [2]. article, we will review current state knowledge regarding experimental shock, by focusing on most recent data obtained newly developed selective inhibitors iNOS.